JPM vs XRAY Stock Comparison
JPM currently leads XRAY in this stock comparison, with AIQ scores of 53 vs 51. The clearest difference is quality, while XRAY has the stronger value profile.
What is the main difference between JPM and XRAY?
JPM leads the current stock comparison as JPMorgan Chase & Co., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
JPMorgan Chase & Co. vs DENTSPLY SIRONA Inc.
JPM leads
JPM leads by 2 AIQ points, primarily on Quality and Risk Resilience, having only recently taken the lead back from XRAY. Wall Street currently favors XRAY on target upside.
Fragile: 3 of 6 evidence groups support JPM, the lead recently changed hands, and its current signal state is conflicted.
JPMorgan Chase & Co.
DENTSPLY SIRONA Inc.
The Algovestiq AIQ Score currently favors JPM over XRAY, 53 versus 51 as of Oct 31, 2026. JPM's advantage is driven primarily by stronger quality and risk resilience, while XRAY holds the stronger value profile. JPM also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors XRAY. 3 of 6 covered evidence groups favor JPM today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. JPM lead: Reversed — XRAY led by 1 AIQ points 30 sessions ago; JPM now leads by 2.
Compare JPMorgan Chase & Co. and DENTSPLY SIRONA Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare JPM and XRAY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value44 vs 73XRAY +29
- Quality46 vs 27JPM +19
- Risk Resilience69 vs 51JPM +18
- Momentum61 vs 53JPM +8
3 of 6 evidence groups favor JPM. JPM’s edge is concentrated in quality and risk resilience; XRAY keeps a meaningful value edge.
What changed since the last close
Latest scored session 2026-10-30, compared against the prior scored session 2026-10-29.
No factor moved materially.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
No factor moved materially.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
JPM's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — JPM and XRAY both carry a full feed there.
The central trade-off
JPM (JPMorgan Chase & Co.): the stronger current systematic profile, led by quality and risk resilience.
XRAY (DENTSPLY SIRONA Inc.): the counter-case, on value, valuation, analyst expectations — but at materially higher volatility, 39.4% against 13%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
JPMJPM on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
XRAYXRAY on combined revenue and EPS growth.
Value
XRAYXRAY on the peer-relative Value factor, by 29 points.
Momentum
JPMJPM on the Momentum factor, by 8 points.
Lower downside
JPMJPM on Risk Resilience, by 18 points.
Analyst upside
XRAYXRAY on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors JPM, analyst targets favor XRAY. That disagreement is the most useful thing on this page.
| Measure | JPM | XRAY | Note |
|---|---|---|---|
| Implied upside to target | +10.7% | +28.8% | XRAY has more room |
| Target dispersion | +32.2% | +65.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 11 | 7 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
Dividend growth
| Dividend metric | JPM | XRAY |
|---|---|---|
| 5Y dividend CAGR | 9.04% | 9.86% |
| 2020 regular DPS | $3.600 | $0.400 |
| 2025 regular DPS | $5.550 | $0.640 |
| Years increased | 5 | 4 |
| No cut in window | Yes | Yes |
| Cohort rank | #120 | #107 |
XRAY grew its split-adjusted regular dividend faster over 2020–2025 — 9.86% a year against JPM's 9.04%. Neither company reduced its regular dividend in any year of the window.
Yield and payout ratio shown elsewhere on this page are current values, not part of the study window.
Split-adjusted regular dividends per share, 2020–2025, excluding special dividends. Research as of Sep 19, 2026.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor JPM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 53 vs 51 |
| Fundamentals | JPMon balance | revenue growth -7.6% vs 2%; EPS growth -27.6% vs 4.6%; TTM ROE 17.9% vs -39.8%; gross margin 63.2% vs 49.5%; operating margin 28.2% vs 11.7% — JPM takes 3 of 5 decided legs, not all of them |
| Valuation | XRAY | Value 44 vs 73 |
| Technicals | JPM | Price vs 50-day -2% vs -2.3%; vs 200-day 5.2% vs -16.9% |
| Risk Resilience | JPM | Risk Resilience 69 vs 51 |
| Analyst expectations | XRAY | Target upside 10.7% vs 28.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of JPM and XRAY and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on JPM.
How the comparison changed
120 daily snapshots · Jul 1 – Oct 30JPM lead: Reversed — XRAY led by 1 AIQ points 30 sessions ago; JPM now leads by 2.
- Today
- JPM +2
- 53 vs 51
- 7 sessions ago
- XRAY +2
- 50 vs 52
- 30 sessions ago
- XRAY +1
- 44 vs 45
- 90 sessions ago
- JPM +7
- 51 vs 44
The lead changed hands 8 times in this window, most recently on Oct 26 when JPM moved ahead of XRAY.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish, conflicted
Only JPM
- Golden Cross Active — bullish, trend, long horizon (6.57%)
- BB Upper Band Breach — bearish, volatility, short horizon
1 bullish / 2 bearish / 2 neutral, conflicted
Only XRAY
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Death Cross Active — bearish, trend, long horizon (16.46%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.67%)
- Downtrend Structure Active — bearish, trend, long horizon
Both carry 1 more signal that do not separate them: MACD Bullish Crossover.
JPM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.9%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.83%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1XRAY closes the Quality gap — currently 19 points behind, the largest single contributor to JPM's edge.
- 2XRAY's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3JPM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
JPM leads on balance| Metric | JPM | XRAY |
|---|---|---|
| Revenue growth (YoY) | -7.6% | 2% |
| EPS growth (YoY) | -27.6% | 4.6% |
| Gross margin | 63.2% | 49.5% |
| Operating margin | 28.2% | 11.7% |
| Return on equity (TTM) | 17.9% | -39.8% |
| Debt to equity | 3.32 | 1.71 |
Performance
JPM leads 4 of 6 windows| Metric | JPM | XRAY |
|---|---|---|
| 1 week (5 sessions) | 1.2% | 4% |
| 1 month (20 sessions) | 2.6% | 6.5% |
| 3 months (63 sessions) | -3.3% | -31.3% |
| 6 months (126 sessions) | 9.7% | -17.8% |
| Year to date | 5.3% | -17.4% |
| 1 year (252 sessions) | 12.9% | -28% |
Technicals
JPM has the stronger structure| Metric | JPM | XRAY |
|---|---|---|
| RSI (14) | 60.9 | 62.9 |
| ADX (14) | 15 | 27.8 |
| Price vs 50-day | -2% | -2.3% |
| Price vs 200-day | 5.2% | -16.9% |
| Volatility (1M, annualized) | 13% | 39.4% |
Risk
JPM is the more resilient| Metric | JPM | XRAY |
|---|---|---|
| Beta | 0.73 | 1.14 |
| Sharpe ratio | 0.41 | -0.53 |
| Sortino ratio | 0.56 | -0.84 |
| Max drawdown | -15.5% | -42.6% |
| Current drawdown | -7.1% | -35.7% |
| Annualized volatility | 22% | 47.9% |
| Value at risk (95%) | -2.4% | -4.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, JPM or XRAY?
On the Algovestiq AIQ Score, JPM is the stronger of the two as of Oct 31, 2026, scoring 53 against XRAY's 51. The edge comes from quality and risk resilience. XRAY is not without a case — it holds the better value profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is JPM or XRAY the better buy right now?
JPM carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.
Why does the AIQ Score favor JPM over XRAY?
The composite weights Quality, Value, Momentum and Risk Resilience. XRAY leads Value by 29 points; JPM leads Quality by 19 points; JPM leads Risk Resilience by 18 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, JPM or XRAY?
Analyst price targets imply +10.7% upside for JPM and +28.8% for XRAY, so the Street currently favors XRAY. That points the opposite way to the AIQ Score, which favors JPM. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, JPM or XRAY?
XRAY is the better-valued of the two on the peer-relative Value factor. XRAY on the peer-relative Value factor, by 29 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, JPM or XRAY?
XRAY on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, JPM or XRAY?
JPM on the Momentum factor, by 8 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, JPM or XRAY?
JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 18 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is JPM more profitable than XRAY?
JPM leads on the comparable margin measures — gross margin 63.2% vs 49.5%; operating margin 28.2% vs 11.7%; ttm roe 17.9% vs -39.8%.
Is JPM's lead over XRAY getting stronger or weaker?
JPM lead: Reversed — XRAY led by 1 AIQ points 30 sessions ago; JPM now leads by 2. This is measured from 120 daily comparison snapshots between 2026-07-01 and 2026-10-30. The lead has changed hands 8 times in that window, most recently on 2026-10-26, when JPM moved ahead of XRAY.
What would change the JPM vs XRAY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XRAY closes the Quality gap — currently 19 points behind, the largest single contributor to JPM's edge; XRAY's Death Cross Active resolves — a bearish trend rule currently active against it; JPM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about JPM and XRAY?
JPM: 2 bullish / 1 bearish, conflicted. XRAY: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on JPM is Golden Cross Active (bullish, long horizon). On XRAY it is Death Cross Active (bearish, long horizon).
Compare JPM and XRAY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.